Selected research
Market Outlook & Growth Opportunities
Global Gene Cell Therapy CDMO Market Outlook and Growth Opportunities 2026
Market perspective
The global Gene Cell Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Gene Cell Therapy CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Gene Cell Therapy CDMO market include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron and Porton, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Gene Cell Therapy CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gene Cell Therapy CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gene Cell Therapy CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Cell Therapy CDMO market.
Gene Cell Therapy CDMO Segment by Company
Catalent
Lonza
Charles River
Oxford Biomedica
Novartis
OBiO
GenScript
Pharmaron
Porton
Resilience
SK Pharmteco
Forge Biologics
Andelyn Biosciences
Roslin CT
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Gene Cell Therapy CDMO Segment by Type
Immune Cells
Stem Cell
Viral Vector
Plasmid DNA
Gene Cell Therapy CDMO Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
Gene Cell Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Gene Cell Therapy CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Gene Cell Therapy CDMO key companies, revenue, market share, and recent developments.
3. To split the Gene Cell Therapy CDMO breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Gene Cell Therapy CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gene Cell Therapy CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Gene Cell Therapy CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Cell Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Cell Therapy CDMO industry.
Chapter 3: Detailed analysis of Gene Cell Therapy CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Gene Cell Therapy CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Gene Cell Therapy CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Gene Cell Therapy CDMO Industry Trends
Table 2. Gene Cell Therapy CDMO Industry Drivers
Table 3. Gene Cell Therapy CDMO Industry Opportunities and Challenges
Table 4. Gene Cell Therapy CDMO Industry Restraints
Table 5. Global Gene Cell Therapy CDMO Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Gene Cell Therapy CDMO Revenue Share by Company (2021-2026)
Table 7. Global Gene Cell Therapy CDMO Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Gene Cell Therapy CDMO Key Company Manufacturing Base & Headquarters
Table 9. Global Gene Cell Therapy CDMO Company, Product Type & Application
Table 10. Global Gene Cell Therapy CDMO Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Gene Cell Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Immune Cells
Table 15. Significant Companies of Stem Cell
Table 16. Significant Companies of Viral Vector
Table 17. Significant Companies of Plasmid DNA
Table 18. Global Gene Cell Therapy CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 19. Global Gene Cell Therapy CDMO Sales Value by Type (2021-2026) & (US$ Million)
Table 20. Global Gene Cell Therapy CDMO Sales Value by Type (2027-2032) & (US$ Million)
Table 21. Global Gene Cell Therapy CDMO Sales Value Share by Type (2021-2026)
Table 22. Global Gene Cell Therapy CDMO Sales Value Share by Type (2027-2032)
Table 23. Significant Companies of Pharmaceutical and Biotechnology Companies
Table 24. Significant Companies of Research and Academic Institutions
Table 25. Significant Companies of Hospital
Table 26. Significant Companies of Others
Table 27. Global Gene Cell Therapy CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global Gene Cell Therapy CDMO Sales Value by Application (2021-2026) & (US$ Million)
Table 29. Global Gene Cell Therapy CDMO Sales Value by Application (2027-2032) & (US$ Million)
Table 30. Global Gene Cell Therapy CDMO Sales Value Share by Application (2021-2026)
Table 31. Global Gene Cell Therapy CDMO Sales Value Share by Application (2027-2032)
Table 32. Global Gene Cell Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global Gene Cell Therapy CDMO Sales Value by Region (2021-2026) & (US$ Million)
Table 34. Global Gene Cell Therapy CDMO Sales Value Share by Region (2021-2026)
Table 35. Global Gene Cell Therapy CDMO Sales Value by Region (2027-2032) & (US$ Million)
Table 36. Global Gene Cell Therapy CDMO Sales Value Share by Region (2027-2032)
Table 37. Global Gene Cell Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Gene Cell Therapy CDMO Sales Value by Country (2021-2026) & (US$ Million)
Table 39. Global Gene Cell Therapy CDMO Sales Value Market Share by Country (2021-2026)
Table 40. Global Gene Cell Therapy CDMO Sales Value by Country (2027-2032) & (US$ Million)
Table 41. Global Gene Cell Therapy CDMO Sales Value Market Share by Country (2027-2032)
Table 42. Catalent Company Information
Table 43. Catalent Business Overview
Table 44. Catalent Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 45. Catalent Gene Cell Therapy CDMO Product Portfolio
Table 46. Catalent Recent Development
Table 47. Lonza Company Information
Table 48. Lonza Business Overview
Table 49. Lonza Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 50. Lonza Gene Cell Therapy CDMO Product Portfolio
Table 51. Lonza Recent Development
Table 52. Charles River Company Information
Table 53. Charles River Business Overview
Table 54. Charles River Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 55. Charles River Gene Cell Therapy CDMO Product Portfolio
Table 56. Charles River Recent Development
Table 57. Oxford Biomedica Company Information
Table 58. Oxford Biomedica Business Overview
Table 59. Oxford Biomedica Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 60. Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
Table 61. Oxford Biomedica Recent Development
Table 62. Novartis Company Information
Table 63. Novartis Business Overview
Table 64. Novartis Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Novartis Gene Cell Therapy CDMO Product Portfolio
Table 66. Novartis Recent Development
Table 67. OBiO Company Information
Table 68. OBiO Business Overview
Table 69. OBiO Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. OBiO Gene Cell Therapy CDMO Product Portfolio
Table 71. OBiO Recent Development
Table 72. GenScript Company Information
Table 73. GenScript Business Overview
Table 74. GenScript Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. GenScript Gene Cell Therapy CDMO Product Portfolio
Table 76. GenScript Recent Development
Table 77. Pharmaron Company Information
Table 78. Pharmaron Business Overview
Table 79. Pharmaron Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Pharmaron Gene Cell Therapy CDMO Product Portfolio
Table 81. Pharmaron Recent Development
Table 82. Porton Company Information
Table 83. Porton Business Overview
Table 84. Porton Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 85. Porton Gene Cell Therapy CDMO Product Portfolio
Table 86. Porton Recent Development
Table 87. Resilience Company Information
Table 88. Resilience Business Overview
Table 89. Resilience Gene Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 90. Resilience Gene Cell Therapy CDMO Product Portfolio
Table 91. Resilience Recent Development
Table 92. SK Pharmteco Company Information
Table 93. SK Pharmteco Business Overview
Table 94. SK Pharmteco Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 95. SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
Table 96. SK Pharmteco Recent Development
Table 97. Forge Biologics Company Information
Table 98. Forge Biologics Business Overview
Table 99. Forge Biologics Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 100. Forge Biologics Gene Cell Therapy CDMO Product Portfolio
Table 101. Forge Biologics Recent Development
Table 102. Andelyn Biosciences Company Information
Table 103. Andelyn Biosciences Business Overview
Table 104. Andelyn Biosciences Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 105. Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
Table 106. Andelyn Biosciences Recent Development
Table 107. Roslin CT Company Information
Table 108. Roslin CT Business Overview
Table 109. Roslin CT Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 110. Roslin CT Gene Cell Therapy CDMO Product Portfolio
Table 111. Roslin CT Recent Development
Table 112. eXmoor Pharma Company Information
Table 113. eXmoor Pharma Business Overview
Table 114. eXmoor Pharma Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 115. eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
Table 116. eXmoor Pharma Recent Development
Table 117. Advanced Therapies Company Information
Table 118. Advanced Therapies Business Overview
Table 119. Advanced Therapies Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 120. Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
Table 121. Advanced Therapies Recent Development
Table 122. Catalent Biologics Company Information
Table 123. Catalent Biologics Business Overview
Table 124. Catalent Biologics Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 125. Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
Table 126. Catalent Biologics Recent Development
Table 127. Patheon Pharma Services Company Information
Table 128. Patheon Pharma Services Business Overview
Table 129. Patheon Pharma Services Gene Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 130. Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
Table 131. Patheon Pharma Services Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Authors List of This Report
Table 134. Secondary Sources
Table 135. Primary Sources
List of Figures
Figure 1. Gene Cell Therapy CDMO Product Image
Figure 2. Global Gene Cell Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million)
Figure 4. Global Gene Cell Therapy CDMO Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Immune Cells Image
Figure 8. Stem Cell Image
Figure 9. Viral Vector Image
Figure 10. Plasmid DNA Image
Figure 11. Global Gene Cell Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 12. Global Gene Cell Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 13. Global Gene Cell Therapy CDMO Sales Value Share by Type (2021-2032)
Figure 14. Pharmaceutical and Biotechnology Companies Image
Figure 15. Research and Academic Institutions Image
Figure 16. Hospital Image
Figure 17. Others Image
Figure 18. Global Gene Cell Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Gene Cell Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Gene Cell Therapy CDMO Sales Value Share by Application (2021-2032)
Figure 21. Global Gene Cell Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 22. Global Gene Cell Therapy CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 23. North America Gene Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 24. North America Gene Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Europe Gene Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 26. Europe Gene Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Asia-Pacific Gene Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 28. Asia-Pacific Gene Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 29. South America Gene Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 30. South America Gene Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Middle East & Africa Gene Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 32. Middle East & Africa Gene Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 33. USA Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. USA Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. USA Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Canada Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Canada Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Canada Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Mexico Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Mexico Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Mexico Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Germany Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Germany Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Germany Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. France Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. France Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. France Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. U.K. Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. U.K. Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. U.K. Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Italy Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Italy Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Italy Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Spain Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Spain Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Spain Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Russia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Russia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Russia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Netherlands Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Netherlands Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Netherlands Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Nordic Countries Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Nordic Countries Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. China Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. China Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. China Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. Japan Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. Japan Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. Japan Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. South Korea Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. South Korea Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. South Korea Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. India Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. India Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. India Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Australia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Australia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Australia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Southeast Asia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Southeast Asia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Brazil Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Brazil Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Brazil Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Argentina Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Argentina Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Argentina Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Chile Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Chile Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Chile Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Colombia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Colombia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Colombia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Peru Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Peru Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Peru Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Saudi Arabia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Saudi Arabia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Israel Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Israel Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Israel Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. UAE Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. UAE Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. UAE Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Turkey Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Turkey Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Turkey Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Iran Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Iran Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Iran Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Egypt Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Egypt Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Egypt Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Years Considered
Figure 118. Research Process
Figure 119. Key Executives Interviewed
Scope & coverage.
Types
- Immune Cells
- Stem Cell
- Viral Vector
- Plasmid DNA
Applications
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Hospital
- Others
Companies covered
- Catalent
- Lonza
- Charles River
- Oxford Biomedica
- Novartis
- OBiO
- GenScript
- Pharmaron
- Porton
- Resilience
- SK Pharmteco
- Forge Biologics
- Andelyn Biosciences
- Roslin CT
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gene Cell Therapy CDMO Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Gene Cell Therapy CDMO Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Gene Cell Therapy CDMO Market Dynamics
- 2.1 Gene Cell Therapy CDMO Industry Trends
- 2.2 Gene Cell Therapy CDMO Industry Drivers
- 2.3 Gene Cell Therapy CDMO Industry Opportunities and Challenges
- 2.4 Gene Cell Therapy CDMO Industry Restraints
3 Gene Cell Therapy CDMO Market by Company
- 3.1 Global Gene Cell Therapy CDMO Company Revenue Ranking in 2025
- 3.2 Global Gene Cell Therapy CDMO Revenue by Company (2021-2026)
- 3.3 Global Gene Cell Therapy CDMO Company Ranking (2024-2026)
- 3.4 Global Gene Cell Therapy CDMO Company Manufacturing Base and Headquarters
- 3.5 Global Gene Cell Therapy CDMO Company Product Type and Application
- 3.6 Global Gene Cell Therapy CDMO Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Gene Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Gene Cell Therapy CDMO Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Gene Cell Therapy CDMO Market by Type
- 4.1 Gene Cell Therapy CDMO Type Introduction
- 4.1.1 Immune Cells
- 4.1.2 Stem Cell
- 4.1.3 Viral Vector
- 4.1.4 Plasmid DNA
- 4.2 Global Gene Cell Therapy CDMO Sales Value by Type
- 4.2.1 Global Gene Cell Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gene Cell Therapy CDMO Sales Value by Type (2021-2032)
- 4.2.3 Global Gene Cell Therapy CDMO Sales Value Share by Type (2021-2032)
5 Gene Cell Therapy CDMO Market by Application
- 5.1 Gene Cell Therapy CDMO Application Introduction
- 5.1.1 Pharmaceutical and Biotechnology Companies
- 5.1.2 Research and Academic Institutions
- 5.1.3 Hospital
- 5.1.4 Others
- 5.2 Global Gene Cell Therapy CDMO Sales Value by Application
- 5.2.1 Global Gene Cell Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gene Cell Therapy CDMO Sales Value by Application (2021-2032)
- 5.2.3 Global Gene Cell Therapy CDMO Sales Value Share by Application (2021-2032)
6 Gene Cell Therapy CDMO Regional Value Analysis
- 6.1 Global Gene Cell Therapy CDMO Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gene Cell Therapy CDMO Sales Value by Region (2021-2032)
- 6.2.1 Global Gene Cell Therapy CDMO Sales Value by Region: 2021-2026
- 6.2.2 Global Gene Cell Therapy CDMO Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gene Cell Therapy CDMO Sales Value (2021-2032)
- 6.3.2 North America Gene Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Gene Cell Therapy CDMO Sales Value (2021-2032)
- 6.4.2 Europe Gene Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Gene Cell Therapy CDMO Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Gene Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Gene Cell Therapy CDMO Sales Value (2021-2032)
- 6.6.2 South America Gene Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Gene Cell Therapy CDMO Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Gene Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
7 Gene Cell Therapy CDMO Country-level Value Analysis
- 7.1 Global Gene Cell Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Gene Cell Therapy CDMO Sales Value by Country (2021-2032)
- 7.2.1 Global Gene Cell Therapy CDMO Sales Value by Country (2021-2026)
- 7.2.2 Global Gene Cell Therapy CDMO Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.7.2 France Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.14.2 China Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.17.2 India Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Gene Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Gene Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Gene Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Catalent
- 8.1.1 Catalent Company Information
- 8.1.2 Catalent Business Overview
- 8.1.3 Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.1.4 Catalent Gene Cell Therapy CDMO Product Portfolio
- 8.1.5 Catalent Recent Developments
- 8.2 Lonza
- 8.2.1 Lonza Company Information
- 8.2.2 Lonza Business Overview
- 8.2.3 Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.2.4 Lonza Gene Cell Therapy CDMO Product Portfolio
- 8.2.5 Lonza Recent Developments
- 8.3 Charles River
- 8.3.1 Charles River Company Information
- 8.3.2 Charles River Business Overview
- 8.3.3 Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.3.4 Charles River Gene Cell Therapy CDMO Product Portfolio
- 8.3.5 Charles River Recent Developments
- 8.4 Oxford Biomedica
- 8.4.1 Oxford Biomedica Company Information
- 8.4.2 Oxford Biomedica Business Overview
- 8.4.3 Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.4.4 Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
- 8.4.5 Oxford Biomedica Recent Developments
- 8.5 Novartis
- 8.5.1 Novartis Company Information
- 8.5.2 Novartis Business Overview
- 8.5.3 Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.5.4 Novartis Gene Cell Therapy CDMO Product Portfolio
- 8.5.5 Novartis Recent Developments
- 8.6 OBiO
- 8.6.1 OBiO Company Information
- 8.6.2 OBiO Business Overview
- 8.6.3 OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.6.4 OBiO Gene Cell Therapy CDMO Product Portfolio
- 8.6.5 OBiO Recent Developments
- 8.7 GenScript
- 8.7.1 GenScript Company Information
- 8.7.2 GenScript Business Overview
- 8.7.3 GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.7.4 GenScript Gene Cell Therapy CDMO Product Portfolio
- 8.7.5 GenScript Recent Developments
- 8.8 Pharmaron
- 8.8.1 Pharmaron Company Information
- 8.8.2 Pharmaron Business Overview
- 8.8.3 Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.8.4 Pharmaron Gene Cell Therapy CDMO Product Portfolio
- 8.8.5 Pharmaron Recent Developments
- 8.9 Porton
- 8.9.1 Porton Company Information
- 8.9.2 Porton Business Overview
- 8.9.3 Porton Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.9.4 Porton Gene Cell Therapy CDMO Product Portfolio
- 8.9.5 Porton Recent Developments
- 8.10 Resilience
- 8.10.1 Resilience Company Information
- 8.10.2 Resilience Business Overview
- 8.10.3 Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.10.4 Resilience Gene Cell Therapy CDMO Product Portfolio
- 8.10.5 Resilience Recent Developments
- 8.11 SK Pharmteco
- 8.11.1 SK Pharmteco Company Information
- 8.11.2 SK Pharmteco Business Overview
- 8.11.3 SK Pharmteco Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.11.4 SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
- 8.11.5 SK Pharmteco Recent Developments
- 8.12 Forge Biologics
- 8.12.1 Forge Biologics Company Information
- 8.12.2 Forge Biologics Business Overview
- 8.12.3 Forge Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.12.4 Forge Biologics Gene Cell Therapy CDMO Product Portfolio
- 8.12.5 Forge Biologics Recent Developments
- 8.13 Andelyn Biosciences
- 8.13.1 Andelyn Biosciences Company Information
- 8.13.2 Andelyn Biosciences Business Overview
- 8.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
- 8.13.5 Andelyn Biosciences Recent Developments
- 8.14 Roslin CT
- 8.14.1 Roslin CT Company Information
- 8.14.2 Roslin CT Business Overview
- 8.14.3 Roslin CT Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.14.4 Roslin CT Gene Cell Therapy CDMO Product Portfolio
- 8.14.5 Roslin CT Recent Developments
- 8.15 eXmoor Pharma
- 8.15.1 eXmoor Pharma Company Information
- 8.15.2 eXmoor Pharma Business Overview
- 8.15.3 eXmoor Pharma Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.15.4 eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
- 8.15.5 eXmoor Pharma Recent Developments
- 8.16 Advanced Therapies
- 8.16.1 Advanced Therapies Company Information
- 8.16.2 Advanced Therapies Business Overview
- 8.16.3 Advanced Therapies Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.16.4 Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
- 8.16.5 Advanced Therapies Recent Developments
- 8.17 Catalent Biologics
- 8.17.1 Catalent Biologics Company Information
- 8.17.2 Catalent Biologics Business Overview
- 8.17.3 Catalent Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.17.4 Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
- 8.17.5 Catalent Biologics Recent Developments
- 8.18 Patheon Pharma Services
- 8.18.1 Patheon Pharma Services Company Information
- 8.18.2 Patheon Pharma Services Business Overview
- 8.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
- 8.18.5 Patheon Pharma Services Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst